ASTRAZENECA CEO SAYS FURTHER BID FOR PFIZER UNLIKELY

Pfizer is unlikely to return with a fresh bid for AstraZeneca, according to the top executive of the pharma giant, who was quoted by Swedish business daily Dagens Industri on 20th December, Bloomberg reports. AstraZeneca saw off a $118 billion approach from Pfizer in May and British takeover rules now allow Pfizer to renew its ...

ABBVIE’S HEPATITIS DRUG PRICED AT 12PC BELOW GILEAD RIVAL

AbbVie and Enanta Pharma’s hepatitis C combination drug will be about 12 per cent cheaper than its rival from Gilead, setting the stage for fierce competition for patients of the liver virus, Bloomberg reports. The cocktail of pills, which will be sold under the name Viekira Pak, will cost $83,319 for a 12-week course of ...

ASTRAZENECA’S LYNPARZA GRANTED US APPROVAL

AstraZeneca has won accelerated approval in the US for an ovarian cancer drug that the company once had scrapped, Bloomberg reports. The FDA cleared the treatment, Lynparza, for women with advanced ovarian cancer who carry a hereditary genetic mutation, a statement from the agency said 19th December. The drug is intended for patients who already ...

EXPRESS SCRIPTS REJECTS GILEAD, SELECTS ABBVIE FOR HEPATITIS C DEAL

AbbVie has agreed to make its hepatitis C drug the exclusive treatment for most patients covered by Express Scripts’ main formulary, a blow against rival Gilead and a move that will escalate the debate over drug prices and insurance benefits, Bloomberg reports. Express Scripts, the biggest manager of prescriptions for US insurance plans when measured ...

CUBISTS’ DRUG FOR ANTIBIOTIC-RESISTANT BACTERIA GRANTED APPROVAL BY FDA

Cubist’s drug to treat complicated urinary tract and intra-abdominal infections was granted US approval on 19th December, highlighting the regulator’s interest in tackling the growing threat of the so-called superbugs, Bloomberg reports. The drug, Zerbaxa, treats infections caused by gram-negative bacteria, a type of antibiotic-resistant pathogens, often called superbugs. These have been linked to 23,000 ...

OREXIGEN DIET PILL RECOMMENDED FOR APPROVAL IN EU

A new diet pill from Orexigen Therapeutics has been recommended for approval in Europe, the EMA announced on 19th December, Reuters reports. The drug, known as Contrave in the US, will be marketed as Mysimba in Europe. The medicine won US approval in September and is a combination of the antidepressant bupropion and Orexigen’s formulation ...

ROCHE ANNOUNCES DEAL TO ACQUIRE BINA TECHNOLOGIES FOR UNDISCLOSED PRICE

Swiss drug maker Roche said on 19th December it had agreed to buy privately-held Bina Technologies for an undisclosed price, the company’s second acquisition in two days, Reuters reports. California-based Bina Technologies provides technology for the processing and management of genomic information. The deal comes on a day when Roche suffered a double blow, as ...

ACTAVIS CONSIDERING BID FOR ALMIRALL TO EXPAND IN EUROPE

Actavis is considering Spanish drug maker Almirall as one of several possible takeover targets, according to sources with knowledge of the matter, Bloomberg reports. Actavis has identified Almirall, which could be valued at around EUR3 billion ($3.7 billion) in a deal, as one of its preferred targets to boost growth in Europe, the people said, ...

RICHARD GREGORY NAMED AS IMMUNOGEN RESEARCH AND CSO

Biotechnology company ImmunoGen has announced the appointment of Richard Gregory as executive VP, research and CSO effective 5th January, 2015, RTTNews.com reports. Gregory will succeed John Lambert, will assume a newly created position of executive VP, distinguished research fellow. He also remains a member of ImmunoGen’s executive team. Lambert joined ImmunoGen in 1987 and has ...

NEW APPS DIRECT PATIENTS TO APPROPRIATE MEDICATION

A new app has been launched which tells US consumers exactly which product is the right one to buy to treat their cold and flu symptoms, pharmatimes.com reports. The first-of-its-kind app, launched by online health information database Iodine, helps US patients sift through the more than 300 cold and flu products available at drugstores to ...